Flagship Pioneering senior partner Raj Panjabi discusses shifting healthcare from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Note: Raj Panjabi was mistakenly introduced as CEO-partner in the interview. His correct title is senior partner.

SGLT2 Inhibitors Cardiovascular and Safety Outcomes in Chronic Diseases by Citeline

Plant-Based Diet Improves Outcomes in Metastatic Breast Cancer by Citeline

Generics Bulletin editors Dave Wallace and Dean Rudge discuss the Global Generics & Biosimilars Awards 2025, providing all the key details of the event coming up in Frankfurt this October, along with tips on how to make the most of your entries and opportunities to get more involved with the event.

Join Andrew Warmington, Manufacturing Editor at Citeline, in conversation with Tom Hickey, Director of Therapeutic Strategy at Novotech, a global full-service clinical CRO dedicated to accelerating the development of advanced and novel therapeutics.

In this episode, recorded live at the European Association for the Study of the Liver Congress (EASL) in Amsterdam, Tom shares invaluable insights into the evolving landscape of hepatology clinical trials and the unique challenges and opportunities shaping the field today.

Listen now to stay ahead in the dynamic world of clinical trials.

An expert from ISACA shares her insights into medtech’s Voluntary Improvement Program (VIP), a collaboration among participants, ISACA, MDIC, and US FDA formed to enhance patient safety and product quality in medical device manufacturing. Listen to learn more about attaining measurable improvements with the VIP.

Largely driven by community pharmacy footfall, France’s self-care market is dynamic and characterized by high levels of innovation, according to French self-care industry association, NèreS. As NèreS’ executive director Luc Besançon explains in this episode of HBW Insight’s Over the Counter podcast, much of this is down to the tireless work of the association. Renaming self-care products as first-line or “premier recours” (first-line) products, identifying medicines that are available OTC in other countries that could be switched in France and quantifying the impact that the revised Urban Wastewater Treatment Directive would have on access to medicines are all strands of NèreS’ pathbreaking recent work.

Timestamps

2:20 – Introductions

3:00 – France’s self-care market

7:50 – Innovation in supplements and devices

11:00 – “Premiere recourse” products

13:00 – Driving reclassification

18:00 – Harmonising Rx-to-OTC switch across Europe

20:00 – Switch environment in France

26:00 – Impact of Urban Wastewater Treatment Directive in France

33:00 – Who should pay?

37:00 – NèreS priorities for 2025

Audio roundup of selected biopharma industry content from Scrip over the business week ended 30 May 2025. In this episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.

https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-L4LQVHCXLRFEDBOU657R5SEMJY/

This episode was produced with the help of AI text-to-voice and voice emulation tools.

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the potential comments that US Food and Drug Administration Commissioner Martin Makary and other senior agency leaders could receive during their pharma CEO listening tour (:30), as well as the impact of Health and Human Services Secretary Robert F. Kennedy Jr.’s decision to change US Centers for Disease Control and Prevention policy and no longer recommend healthy children and pregnant women receive COVID-19 vaccines (15:47).

More On These Topics From The Pink Sheet

US FDA Makary’s Pharma CEO Tour Goes Against Transparency Rhetoric: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fda-makarys-pharma-ceo-tour-goes-against-transparency-rhetoric-3E5RP5IATVD73DRPQHZPSTHKRA/

HHS Rescinds COVID-19 Vaccine Advice, Usurping US CDC Role: https://insights.citeline.com/pink-sheet/vaccines/hhs-rescinds-covid-19-vaccine-advice-usurping-us-cdc-role-YNFI7TU5CFGERIGFG7ISOJ4X5Q/

The uncertainty surrounding changes at the FDA and other market dynamics is reshaping the global drug development landscape. In this webinar, CRO regulatory leaders will summarize the collective experience of the biotech companies we’ve spoken to recently. We will explore:

• The impact of the FDA leadership changes, staffing cuts, and return to office mandates in reshaping regulatory priorities.

• Trends we’re observing from biotech sponsors on the decision of whether or not to keep trials in the US.

• The broader implications for industry investment, pipeline prioritization strategies, and international responses.

This episode is part 1 of 4 in the series “Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials”, featuring insights from Novotech on evolving trends impacting global clinical development. Stay tuned for the next episode, where we’ll continue exploring the key forces shaping the future of clinical trials.